Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Harvard Apparatus Regenerative Technology, Inc.

Get SEC filing alerts via email and in your feed for Harvard Apparatus Regenerative Technology, Inc.

HRGN

Harvard Apparatus Regenerative Technology, Inc.

About Harvard Apparatus Regenerative Technology, Inc.

Harvard Apparatus Regenerative Technology develops regenerative medicine solutions using patient-derived stem cells and biocompatible scaffolds to restore organ function, primarily targeting the gastrointestinal tract and airways. Its innovative tissue-engineered implants aim to replace or repair damaged organs without permanent artificial devices or donor organs. The company focuses on clinical development, regulatory approval, and international expansion, collaborating with leading medical institutions to advance minimally invasive regenerative therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Harvard Apparatus Regenerative Technology, Inc.

1
1
Harvard Apparatus Regenerative Technology, Inc. Harvard Apparatus Regenerative Technology Reports 402% Revenue Growth but Faces Financial Challenges

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Harvard Apparatus Regenerative Technology, Inc. Harvard Apparatus Regenerative Technology Reports 64% Revenue Growth but Faces Operating Losses

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Harvard Apparatus Regenerative Technology, Inc. Harvard Apparatus Reports 108% Revenue Growth in Q3 2025 Amid Ongoing Losses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Harvard Apparatus Regenerative Technology, Inc. Harvard Apparatus Reports 466% Increase in Product Revenue for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Harvard Apparatus Regenerative Technology, Inc. Harvard Apparatus Reports Q1 2025 Financial Results, Sees Revenue Decline and Operating Loss Improvement

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Harvard Apparatus Regenerative Technology, Inc. Harvard Apparatus Regenerative Technology Reports 2024 Financial Results with Revenue Growth and Operating Losses

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Harvard Apparatus Regenerative Technology, Inc. Harvard Apparatus Regenerative Technology Reports 48% Product Revenue Growth, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments